AUNP-12  (Synonyms: NP-12)

AUNP-12 (NP-12) is a peptide antagonist of the PD-1 signaling pathway, displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions. AUNP-12 exhibits immune activation, excellent antitumor activity, and potential for better management of immune-related adverse events (irAEs)^[1].

PD-1 signaling pathway^[1]

AUNP-12 displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions ^[1].
AUNP-12 rescues the proliferation in the mouse splenocyte assay system, with average EC₅₀ values of 17 nM and 16.6 nM against rmPD-L1 and rmPD-L2 respectively^[1].
AUNP-12 is also able to significantly rescue recombinant human PD-L1 and PD-L2 mediated inhibition of in vitro human PBMC proliferation, with average EC₅₀ values of 63.3 nM and 44.1 nM against PD-L1 and PD-L2 respectively^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

3261.55

C₁₄₂H₂₂₆N₄₀O₄₈

1353563-85-5

Solid

White to off-white

H-SNTSESFKF(H-SNTSESF)RVTQLAPKAQIKE-NH2

[3H]N=[S](F)([NH])S(CC[Si](C)(C)C)(=O)=O.[SNTSESFKFRVTQLAPKAQIKE-NH2].[I]

Room temperature in continental US; may vary elsewhere.

Sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

• [1]. Sasikumar PG, et al. A Rationally Designed Peptide Antagonist of the PD-1 Signaling Pathway as an Immunomodulatory Agent for Cancer Therapy. Mol Cancer Ther. 2019 Jun;18(6):1081-1091.  [Content Brief]